Johnson & Johnson’s (J&J) Lazcluze (lazertinib) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Takeda and Protagonist Therapeutics have shared positive top-line results from a phase 3 trial of rusfertide in the rare ...

AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...

Medicine is constantly evolving, but progress is only meaningful if it reaches everyone. Health outcomes are shaped not just ...

Who says remote work can't be fun? Discover creative ways to boost morale and keep your life sciences team engaged with ...

Red hot preview coming to you today, as we’re soon to launch our new Media Vitals Global HCP report, offering insights around ...

One-size-fits-all doesn’t fit – in today’s global marketplace, personalization is the best way to engage key audiences. In ...

Novo Nordisk and Gensaic have entered into a partnership worth up to $354m to develop new therapies for cardiometabolic ...

Eli Lilly’s Jaypirca (pirtobrutinib) has been recommended by the European Medicines Agency’s (EMA) human medicines committee ...

Regeneron Pharmaceuticals has received a positive opinion from the European Medicines Agency’s human medicines committee for ...

The Healthcare Communications Association has recently revitalised its long-established efforts to evaluate impact (those of ...

One of the toughest challenges of educating many African women about female cancers and disease prevention is overcoming ...